Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase III Antibiotic Garenoxacin Will Be Out-Licensed, Schering Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Schering-Plough will out-license U.S. rights to the Phase III quinolone antibiotic garenoxacin due to potential conflicts of interest related to the company's primary care marketing agreement with Bayer

You may also be interested in...



Schering-Plough Drops Garenoxacin NDA, But Leaves Door Open For Resubmission

Sept. 11 advisory committee meeting on antibiotic cancelled.

Schering-Plough Drops Garenoxacin NDA, But Leaves Door Open For Resubmission

Sept. 11 advisory committee meeting on antibiotic cancelled.

Schering’s Antibiotic Garenoxacin Gets Advisory Committee Date

FDA's Anti-Infective Drugs Advisory Committee will discuss Schering-Plough's antibiotic garenoxacin on Sept. 11, according to a Federal Register pre-publication announcement July 24

Related Content

Topics

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel